about
Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchisepticaSNP-based typing: a useful tool to study Bordetella pertussis populationsProteomics-identified Bvg-activated autotransporters protect against bordetella pertussis in a mouse model.Complete Genome Sequences of 11 Bordetella pertussis Strains Representing the Pandemic ptxP3 Lineage.Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains.Comparative gene expression profiling in two congenic mouse strains following Bordetella pertussis infection.The role of Toll-like receptor-4 in pertussis vaccine-induced immunity.Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strainsMolecular evolution of the two-component system BvgAS involved in virulence regulation in BordetellaBordetella pertussis strains with increased toxin production associated with pertussis resurgence.Comparative genomics of prevaccination and modern Bordetella pertussis strains.Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis.Studies on Prn variation in the mouse model and comparison with epidemiological dataThe vaccine potential of Bordetella pertussis biofilm-derived membrane proteins.Multilocus sequence typing of Bordetella pertussis based on surface protein genes.Bordetella pertussis clones identified by multilocus variable-number tandem-repeat analysis.Small mutations in Bordetella pertussis are associated with selective sweeps.Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen.Complete Genome Sequences of Bordetella pertussis Isolates B1917 and B1920, Representing Two Predominant Global Lineages.Bordetella pertussis naturally occurring isolates with altered lipooligosaccharide structure fail to fully mature human dendritic cellsComplement evasion by Bordetella pertussis: implications for improving current vaccinesStudying Bordetella pertussis populations by use of SNPeX, a simple high-throughput single nucleotide polymorphism typing method.Seroprevalence of pertussis in the Gambia: evidence for continued circulation of bordetella pertussis despite high vaccination rates.Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains.Effects of a diphtheria-tetanus-acellular pertussis vaccine on immune responses in murine local lymph node and lung allergy modelsGenetic Variation of Bordetella pertussis in Austria.Lung response to Bordetella pertussis infection in mice identified by gene-expression profilingLipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.Temporal trends in Bordetella pertussis populations, Denmark, 1949-2010.Laboratory Diagnosis of Pertussis.Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis.Two-component cluster analysis of a large serodiagnostic database for specificity of increases of IgG antibodies against pertussis toxin in paired serum samples and of absolute values in single serum samplesBordetella pertussis Isolates from Argentinean Whooping Cough Patients Display Enhanced Biofilm Formation Capacity Compared to Tohama I Reference Strain.Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses.Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009.Preclinical and clinical safety studies on DNA vaccines.The case for maternal vaccination against pertussis.Multiple-locus variable-number tandem repeat analysis of Dutch Bordetella pertussis strains reveals rapid genetic changes with clonal expansion during the late 1990s.Immunodominance in mouse and human CD4+ T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin.Improving pertussis vaccination.
P50
Q21131623-6615753F-4203-4F32-9C12-74F524034390Q28744176-97CC2818-E3E3-445F-BEF8-7AC267963FF2Q30208978-1B51B3E2-D923-4BDC-B9ED-001894E58014Q30381881-8FFF0C14-0060-45A1-A636-0DF62E761D4BQ33299470-89FCDE3C-2EAA-41A1-9F54-138CE1A4A021Q33302556-1FA8CCD1-6A64-47CF-B83D-0EB86F112B76Q33337196-DB4D9358-FD7E-4B70-A642-2212265FDADDQ33347857-804C15A4-A66E-44B0-8FDB-F9770BD9EFB0Q33502712-58816F9B-3827-449D-AB4B-2F57F567AD32Q33628654-5D886800-8628-43CB-A64B-45BA1110AB6FQ33744416-B3A5474C-593D-41E5-BE88-FFEA8B222754Q33769972-DD0C224E-9635-49C6-B266-C04CE057C246Q33862635-6F22D4C4-A52E-4FE1-8ACC-145887A26F40Q34113606-63B76872-38DE-423D-9CF0-F281ED8EF525Q34196111-BB337B18-18A9-42FC-986C-51DC0BF2291BQ34216098-9275713C-AF02-42ED-8AF5-42561F928675Q34431224-887E7D44-289E-4FFF-B05B-15BE5A6CB7D5Q34759839-25EFF1E7-123D-4724-9966-5C94B408083CQ34774378-2C7F85AA-9FFF-4B7E-99BB-5AC937C8A067Q34889754-E6BA04DE-19DB-4466-BF7D-FA7ACC277E7CQ35197120-AA7D5904-EC81-41EB-91BA-6FD037699BD5Q35331672-82758E61-DE4A-45A5-9EF1-9491B650601BQ35566869-AFC6F7C0-6681-4F10-A59B-DCB1800978B9Q35690068-BDC5C743-7D6B-4107-8F6F-0A393A8D2CA1Q35690073-66B62EB1-A7C7-4FAC-B9C7-A7C0F4F4432DQ35693639-984F8BD0-43B5-4AE3-9786-0FDB836DC55CQ35881038-DC98D15F-681A-493F-B956-AFD9AC2D9CC4Q35946895-79A6CE15-0C0E-4FC1-B28C-DED8B337161BQ35979587-91B98CF5-78EE-429F-8E04-D5F1A7F7C1DFQ36073693-75C62EE8-7E07-4CFB-8222-5B59269D0FB1Q36098742-6AA27060-52D2-4646-8223-A8EB95D689DDQ36191623-86D6C35A-FADF-4B86-B98C-73EB12A48753Q36354539-E95F9573-1E40-472A-875C-7F761772A69EQ36483610-FCC89367-133B-4AB1-8758-C3759166228FQ36558999-0D8D087E-4398-45B7-9AB1-AC783836998FQ36609096-3DF8B3C8-9FF9-4900-8775-28B894D8B666Q36835244-280781F4-B920-40A1-8C5C-92C0FBD112D2Q37006836-604B975F-20B5-4B00-834A-B7FA9214B12BQ37075449-4B9E4523-148E-4DF1-AD22-76594EBF6CCBQ37400939-DA2680E8-3F4E-4934-A126-89D9F3553C95
P50
name
Frits R Mooi
@en
type
label
Frits R Mooi
@en
prefLabel
Frits R Mooi
@en